The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabretta, Eleonora, Hamadani, Mehdi, Zinzani, Pier Luigi, Caimi, Paolo, Carlo-Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Blood Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335500/
https://www.ncbi.nlm.nih.gov/pubmed/35580172
http://dx.doi.org/10.1182/blood.2021014663
_version_ 1784759355356217344
author Calabretta, Eleonora
Hamadani, Mehdi
Zinzani, Pier Luigi
Caimi, Paolo
Carlo-Stella, Carmelo
author_facet Calabretta, Eleonora
Hamadani, Mehdi
Zinzani, Pier Luigi
Caimi, Paolo
Carlo-Stella, Carmelo
author_sort Calabretta, Eleonora
collection PubMed
description Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after 2 lines of systemic therapy based on a trial showing a 48.3% overall response rate. The spectrum of its clinical applications is expanding and is now being tested in other B-cell malignancies.
format Online
Article
Text
id pubmed-9335500
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-93355002022-11-16 The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma Calabretta, Eleonora Hamadani, Mehdi Zinzani, Pier Luigi Caimi, Paolo Carlo-Stella, Carmelo Blood Blood Spotlight Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after 2 lines of systemic therapy based on a trial showing a 48.3% overall response rate. The spectrum of its clinical applications is expanding and is now being tested in other B-cell malignancies. American Society of Hematology 2022-07-28 /pmc/articles/PMC9335500/ /pubmed/35580172 http://dx.doi.org/10.1182/blood.2021014663 Text en © 2022 by The American Society of Hematology. https://creativecommons.org/licenses/by-nc-nd/4.0/Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Blood Spotlight
Calabretta, Eleonora
Hamadani, Mehdi
Zinzani, Pier Luigi
Caimi, Paolo
Carlo-Stella, Carmelo
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
title The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
title_full The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
title_fullStr The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
title_full_unstemmed The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
title_short The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
title_sort antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large b-cell lymphoma
topic Blood Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335500/
https://www.ncbi.nlm.nih.gov/pubmed/35580172
http://dx.doi.org/10.1182/blood.2021014663
work_keys_str_mv AT calabrettaeleonora theantibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT hamadanimehdi theantibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT zinzanipierluigi theantibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT caimipaolo theantibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT carlostellacarmelo theantibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT calabrettaeleonora antibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT hamadanimehdi antibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT zinzanipierluigi antibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT caimipaolo antibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma
AT carlostellacarmelo antibodydrugconjugateloncastuximabtesirineforthetreatmentofdiffuselargebcelllymphoma

Ejemplares similares